688670 Jiangsu Gdk Biological Technology
- 17.46
- -0.26-1.47%
Jiangsu Gdk Biological Technology News
Jindick (688670.SH): Net loss of 21.494 million yuan in the first quarter
On April 15, Ge Longhui (688670.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 50,181 million yuan, a year-on-year decrease of 95.28%; net profit attributable to shareholders of listed companies - 21.494 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 244.23,500 yuan; and basic earnings per share - 0.17 yuan.
Jindick (688670.SH) reported 2023 annual results, with a net loss of 70.993 million yuan, which changed from profit to loss over the previous year
According to Zhitong Finance App News, Jindick (688670.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 135 million yuan, a year-on-year decrease of 57.74%; net loss attributable to shareholders of listed companies was 72.503 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies was deducted from non-recurring profit and loss of 72.579 million yuan, year-on-year from profit to loss; basic loss per share was 0.58 yuan/share. During the reporting period, operating revenue decreased by 57.74% compared to the same period last year, mainly due to the temporary suspension of production due to a sudden heavy rain in Taizhou, where the company is located in July 2023, until
Kindick (688670.SH): Net loss of 657.796 million yuan in 2023
On February 23, Ge Longhui (688670.SH) announced the 2023 annual results report. The company achieved operating income of 139.659 million yuan in 2023, a year-on-year decrease of 56.05%; realized net profit attributable to the owner of the parent company - 657.796 million yuan, a year-on-year decrease of 258.34%; realized net profit attributable to the owner of the parent company after deducting non-recurring gains and losses - 74.51 million yuan, a year-on-year decrease of 429.42%.
More Unpleasant Surprises Could Be In Store For Jiangsu Gdk Biological Technology Co., Ltd's (SHSE:688670) Shares After Tumbling 27%
Unfortunately for some shareholders, the Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) share price has dived 27% in the last thirty days, prolonging recent pain. The drop over the last 3
Kindick (688670.SH) issued a forecast loss and is expected to have a net loss of 65 million yuan in 2023
Kindick (688670.SH) released its 2023 annual performance forecast, which is expected to generate revenue for the full year of 2023...
Kindick (688670.SH): The freeze-dried human rabies vaccine (Vero cells) is being declared to the national CDE in accordance with the procedure
On January 23, Ge Longhui (688670.SH) said on the investor interactive platform that the company's freeze-dried human rabies vaccine (Vero cells) is being reported to the national CDE in accordance with the procedures. Due to the strict science of registration of the new drug, the review cycle is long, so stay tuned for further progress.
Some Confidence Is Lacking In Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) As Shares Slide 26%
Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive perf
Kim Dick (688670.SH): “New quadrivalent influenza virus lysis workshop project” and innovative vaccine research and development project postponed
On December 25, Gelonghui (688670.SH) announced that the equipment for the “New Quadrivalent Influenza Virus Cracking Workshop Project” has all been put in place, and several rounds of commissioning have been carried out in the early stages. It was originally planned to reach the intended useable state in January 2024. Later, due to the external epidemic, the temporary shutdown of the company, etc., the project commissioning and verification work lagged behind the original plan. A new round of debugging and verification was needed. GMP verification and drug administration department inspection are lagging behind the original plan. While the investment content, total investment amount, and implementation entity of the fund-raising project remain unchanged, it was decided, after scientific evidence, that the fund-raising project would “build a new four-price model”
Kim Dick (688670.SH): The influenza vaccine market is not a stock game, but an incremental competition
Glonghui December 19|Kim Dick (688670.SH) said on the investor interactive platform that the influenza vaccine market is not a stock game, but an incremental competition. What is significantly different from other vaccines is that the influenza vaccine is given every year and covers people of all ages. The market space is large and demand is stable, so companies in the industry are developing quadrivalent influenza vaccines one after another to expand production capacity. We know that the vaccine has a large investment in R&D (8 to 1 billion yuan) and a long cycle (8-10 years). The increase in entrants shows the industry's confidence in future market growth from another side. Competition within the influenza vaccine industry is not a stock boom
Kim Dick (688670.SH): Currently, the domestic influenza vaccination rate is very low, far below the 50% vaccination rate in Europe and the US and 20%-30% in East Asia
GLONGHUI December 19丨Kim Dick (688670.SH) said on the investor interactive platform that there is broad room for growth in the influenza vaccine market. Currently, the domestic influenza vaccination rate is very low, far below the 50% vaccination rate in Europe and the US and 20%-30% in East Asia. Compared with the 75% target influenza vaccination rate recommended by the World Health Organization for key population groups, the current vaccination rate for key population groups in China is less than 5%, yet the key population in Europe, America, and other regions of East Asia has exceeded 60%. The key population base for children under 18 and people aged 60 and above in China is about 517 million, and the overall vaccination rate for key population groups is also very low
Kim Dick (688670.SH): The quadrivalent influenza vaccine for the 2023-2024 influenza season was issued in batches
GLONGHUI December 19丨Jindick (688670.SH) announced that as of the disclosure date of this announcement, a total of 8 batches of the company's quadrivalent influenza vaccine for the 2023-2024 influenza season have been issued by the Central Inspection Institute and can be marketed. The company is selling and delivering goods to the market in an orderly manner to meet people's influenza vaccination needs. However, we are now nearing the end of sales for the 2023-2024 influenza season, and there is still uncertainty about the specific product sales situation.
The National Health and Health Commission suggests getting the influenza vaccine as soon as possible, and sorting out China's influenza vaccine market pattern and enterprises
① At present, influenza vaccines from several domestic manufacturers have been approved for the market, of which 11 manufacturers have supplied them during the 2022-2023 influenza season; ② The Zhongtai Securities Research Report points out that with the arrival of the influenza season, it is recommended to pay attention to investment opportunities for relevant testing, vaccine and drug companies.
Guolian Securities: Respiratory infectious diseases combined with high incidence seasons are optimistic about investment opportunities in the diagnosis and treatment industry chain
Vaccines are the most effective means of preventing infectious diseases, and the high incidence of influenza is expected to accelerate the release of demand for vaccination.
Kim Dick: Sales of the quadrivalent influenza vaccine will resume after passing approval by the Central Inspection Institute | Direct impact on performance
① The company's influenza vaccine workshop temporarily stopped production, causing delays in the launch and sales of new influenza season products. Sales in the third quarter were zero, which will also adversely affect the annual performance; ② Quadrivalent influenza vaccine products still need to pass the batch approval of the Central Inspection Institute before sales can resume.
Kim Dick (688670.SH): The company's freeze-dried human rabies vaccine (Vero cells) has completed phase III clinical trials and obtained clinical summary reports
Gelonghui, November 24|Kim Dick (688670.SH) said on the investor interactive platform that the company's freeze-dried human rabies vaccine (Vero cells) has completed phase III clinical trials and obtained clinical summary reports. Due to the strict science of new drug registration and a long review cycle, the company is reporting to the national CDE in accordance with the procedures.
[BT Financial Report Instantaneous Analysis] Jindick's 2023 Quarterly Report: Operating income and net profit declined, and net cash flow increased significantly
This financial report was announced on 2023-10-27 16:26:03 Jiangsu Jindike Biotechnology Co., Ltd. (stock code: 688670) is an enterprise focusing on R&D, production and sales of human vaccines. Its main products include human vaccines to prevent infectious diseases such as influenza, rabies, chicken pox, shingles, and pneumonia. The company has marketed a quadrivalent influenza virus lysis vaccine. The vaccine is superior to the standards of the Chinese Pharmacopoeia and European Pharmacopoeia in terms of immune efficacy and safety. In terms of assets and liabilities, the total assets of Jindik at the end of the third quarter of 2023 are
Should Weakness in Jiangsu Gdk Biological Technology Co., Ltd's (SHSE:688670) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Jiangsu Gdk Biological Technology's (SHSE:688670) recent performance, when its stock has declined 14% over the past week. But if you pay close attention, y
The wave of influenza vaccinations is moving southward, with intermittent shortages of stock in some regions, and the discontinuation of Kindick Q3 production has led to market changes
GLONGHUI, Oct. 14 | A reporter from the Finance Federation conducted field research on the vaccination situation at first-line medical institutions in Shenzhen, Nanjing, Shanghai and other places and found that the peak of influenza vaccination is gradually spreading from north to south, and there have been intermittent shortages of influenza vaccines in parts of Shenzhen. Companies and experts told the Finance Federation reporter that the current influenza epidemic intensity in the country is moderate, and the vaccine supply is generally stable and controllable. Special attention needs to be paid to the peak of the influenza epidemic at the beginning of next year. Also, since Kindik stopped production in the third quarter due to the floods, the domestic influenza vaccine market changed markedly. Old “players” such as Hualan Vaccine and Baike Biotech actively “filled in the blanks”, and new ones such as Clover Biotech
Kim Dick (688670.SH): The influenza vaccine workshop, which stopped production due to torrential rain, has returned to a producible state and production still needs to be verified through simulation tests
According to the Zhitong Finance App, Jin Dick (688670.SH) announced that the company's influenza vaccine workshop will temporarily stop production from July 15, 2023 due to heavy rain due to water seepage. The company actively organizes personnel to treat the workshop environment and take specific measures to promote the restoration of the workshop environment and the resumption of production. As of the disclosure deadline of the announcement, continuous environmental monitoring by the company's quality department and environmental monitoring by a third party agency confirmed that the environment in the company's influenza vaccine workshop had been restored and reached a producible state. Restoring the environment in the influenza vaccine workshop is the first step in resuming production. Currently, only the workshop has returned to a production-ready state; it is not yet possible to carry out official products
Kim Dick (688670.SH) Releases First Half Results, Turns Net Profit Loss to Profit to $3508.1 Million
According to the Zhitong Finance App, Jin Dick (688670.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income of 127 million yuan, an increase of 675.48% over the previous year; realized net profit attributable to shareholders of listed companies of 3508.1 million yuan, turning a loss into a profit from the previous year; realized net profit attributable to shareholders of listed companies of 3.06 million yuan, turning a loss into a profit; basic earnings per share of 0.28 yuan/share. During the reporting period, the sharp increase in revenue was mainly due to the high incidence of influenza outbreaks in many parts of China in the first quarter of 2023, which boosted sales of influenza vaccines
Analysis
Price Target
No Data
